Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial
- PMID: 20550679
- PMCID: PMC2903532
- DOI: 10.1186/1756-9966-29-70
Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial
Abstract
Background: Intra-arterial radioembolization with yttrium-90 microspheres ( 90Y-RE) is an increasingly used therapy for patients with unresectable liver malignancies. Over the last decade, radioactive holmium-166 poly(L-lactic acid) microspheres ( 166Ho-PLLA-MS) have been developed as a possible alternative to 90Y-RE. Next to high-energy beta-radiation, 166Ho also emits gamma-radiation, which allows for imaging by gamma scintigraphy. In addition, Ho is a highly paramagnetic element and can therefore be visualized by MRI. These imaging modalities are useful for assessment of the biodistribution, and allow dosimetry through quantitative analysis of the scintigraphic and MR images. Previous studies have demonstrated the safety of 166Ho-PLLA-MS radioembolization ( 166Ho-RE) in animals. The aim of this phase I trial is to assess the safety and toxicity profile of 166Ho-RE in patients with liver metastases.
Methods: The HEPAR study (Holmium Embolization Particles for Arterial Radiotherapy) is a non-randomized, open label, safety study. We aim to include 15 to 24 patients with liver metastases of any origin, who have chemotherapy-refractory disease and who are not amenable to surgical resection. Prior to treatment, in addition to the standard technetium-99m labelled macroaggregated albumin ( 99mTc-MAA) dose, a low radioactive safety dose of 60-mg 166Ho-PLLA-MS will be administered. Patients are treated in 4 cohorts of 3-6 patients, according to a standard dose escalation protocol (20 Gy, 40 Gy, 60 Gy, and 80 Gy, respectively). The primary objective will be to establish the maximum tolerated radiation dose of 166Ho-PLLA-MS. Secondary objectives are to assess tumour response, biodistribution, performance status, quality of life, and to compare the 166Ho-PLLA-MS safety dose and the 99mTc-MAA dose distributions with respect to the ability to accurately predict microsphere distribution.
Discussion: This will be the first clinical study on 166Ho-RE. Based on preclinical studies, it is expected that 166Ho-RE has a safety and toxicity profile comparable to that of 90Y-RE. The biochemical and radionuclide characteristics of 166Ho-PLLA-MS that enable accurate dosimetry calculations and biodistribution assessment may however improve the overall safety of the procedure.
Trial registration: ClinicalTrials.gov NCT01031784.
Figures
Similar articles
-
Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.Lancet Oncol. 2012 Oct;13(10):1025-34. doi: 10.1016/S1470-2045(12)70334-0. Epub 2012 Aug 22. Lancet Oncol. 2012. PMID: 22920685 Clinical Trial.
-
(⁹⁹m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: a quantitative evaluation in patients treated with ¹⁶⁶Ho-microspheres.Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1965-75. doi: 10.1007/s00259-014-2784-9. Epub 2014 May 13. Eur J Nucl Med Mol Imaging. 2014. PMID: 24819055 Clinical Trial.
-
Safety of a Scout Dose Preceding Hepatic Radioembolization with 166Ho Microspheres.J Nucl Med. 2015 Jun;56(6):817-23. doi: 10.2967/jnumed.115.155564. Epub 2015 Apr 30. J Nucl Med. 2015. PMID: 25931477
-
Holmium-166 Microsphere Radioembolization of Hepatic Malignancies.Semin Nucl Med. 2019 May;49(3):237-243. doi: 10.1053/j.semnuclmed.2019.01.008. Epub 2019 Feb 1. Semin Nucl Med. 2019. PMID: 30954190 Review.
-
Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres.Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):559-75. doi: 10.1007/s00259-015-3157-8. Epub 2015 Sep 4. Eur J Nucl Med Mol Imaging. 2016. PMID: 26338177 Free PMC article. Review.
Cited by
-
Transarterial Radioembolization: Overview of Radioembolic Devices.Semin Intervent Radiol. 2023 Nov 2;40(5):461-466. doi: 10.1055/s-0043-1772814. eCollection 2023 Oct. Semin Intervent Radiol. 2023. PMID: 37927522 Review. No abstract available.
-
Microspheres as a Carrier System for Therapeutic Embolization Procedures: Achievements and Advances.J Clin Med. 2023 Jan 24;12(3):918. doi: 10.3390/jcm12030918. J Clin Med. 2023. PMID: 36769566 Free PMC article. Review.
-
Intratumoral injection of holmium-166 microspheres as neoadjuvant therapy of soft tissue sarcomas in dogs.Front Vet Sci. 2022 Nov 1;9:1015248. doi: 10.3389/fvets.2022.1015248. eCollection 2022. Front Vet Sci. 2022. PMID: 36387397 Free PMC article.
-
Holmium-166 Radioembolization: Current Status and Future Prospective.Cardiovasc Intervent Radiol. 2022 Nov;45(11):1634-1645. doi: 10.1007/s00270-022-03187-y. Epub 2022 Jun 21. Cardiovasc Intervent Radiol. 2022. PMID: 35729423 Free PMC article. Review.
-
Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies.Semin Intervent Radiol. 2021 Oct;38(4):438-444. doi: 10.1055/s-0041-1735526. Epub 2021 Oct 7. Semin Intervent Radiol. 2021. PMID: 34629711 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical